Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-12-31

Clinical Trial Update: Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder [Phase 3]

View source ↗

Summary

Open-label Phase 3 study of duloxetine as monotherapy for Posttraumatic Stress Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Duloxetine (DULOXETINE)

Snippet

Sponsor: Canive, Jose M., M.D. | Conditions: Posttraumatic Stress Disorders | Phase 3 | Status: UNKNOWN